California Methadone Take-Home Regulations and Requirements

California’s methadone take-home regulations changed on October 1, 2025, and now follow a three-tier federal framework tied to how long a patient has been in an Opioid Treatment Program. A patient who meets the clinical criteria can receive up to a 7-day supply during the first two weeks, up to 14 days between days 15 and 30, and up to 28 days from day 31 onward. Every dose above the daily observed minimum still depends on the prescriber’s judgment, so these numbers are ceilings rather than automatic entitlements.

Current Take-Home Supply Limits

Under the revised state and federal rules, take-home methadone is governed by three tiers based on time in treatment. The prescriber sets the actual number of doses within each tier’s ceiling and documents the reasoning in the patient’s clinical record.¹

Days 1 through 14: no more than a 7-day take-home supply. New patients often start with just one or two days while the clinic builds a picture of how they’re responding.
Days 15 through 30: no more than a 14-day take-home supply.
Day 31 onward: no more than a 28-day take-home supply.

These limits sit on top of doses provided for days the clinic is closed, including Sundays and holidays, which any patient in comprehensive treatment may receive regardless of time in the program.¹

Not every clinic moves patients to the ceiling as quickly as the regulation allows. Many programs ramp up gradually within a tier even though the rule doesn’t require them to, so a patient in month two may still be receiving a shorter supply than the 14-day maximum. That’s a program-level decision, not a legal one, and it’s worth asking your prescriber directly what their pace looks like.

Eligibility Criteria the Prescriber Weighs

Regardless of which tier applies, the medical director or program physician must evaluate a set of clinical factors before granting any take-home dose. California’s criteria under Section 10370 of Title 9 require documented consideration of the following:²

No illicit drug use or substance abuse, including alcohol. Drug screens must be negative for unauthorized substances and positive for the prescribed medication.
Regular attendance at both medication dosing and required counseling sessions.
No serious behavioral problems at the clinic.
No known criminal activity, with drug sales specifically named.
A stable home environment that supports safe storage and responsible use.
Length of time in treatment, which gives the prescriber a longer track record to evaluate.
Demonstrated ability to transport and store the medication securely.

Federal criteria under the revised 42 CFR Part 8 track closely with California’s and add absence of known recent diversion activity as a standalone factor, along with room for the prescriber to weigh anything else relevant to patient safety and public health.¹ Most clinics treat the state and federal lists as one combined checklist.

Drug Testing Requirements

Drug screening is central to keeping take-home eligibility. Federal rules require Opioid Treatment Programs to conduct at least eight random drug tests per patient per year using FDA-authorized methods.³ California goes further, calling for a current monthly body specimen that is negative for illicit drugs and positive for the prescribed narcotic medication.² That works out to at least twelve tests per year for California patients.

When a test comes back positive for unauthorized substances, the prescriber must reassess take-home status. For supply levels equivalent to the old Steps I through V, the patient cannot have evidence of illicit drug use, alcohol abuse, or criminal activity within the preceding 30 days. For the highest supply level, equivalent to a one-month take-home, that lookback runs a full year.

Storage, Safe Handling, and Callbacks

Take-home methadone must be stored in a locked container and kept out of the reach of children and anyone else in the household. Before approving take-homes, the clinician assesses the patient’s living situation, including whether children are present, whether other household members use drugs, and whether a lockable storage area is available. Some programs conduct home visits to verify these conditions, though that isn’t universally required.

Patients should use the medication exactly as prescribed and should never transfer it to any container other than the one the clinic provides. Sharing or selling take-home doses is a federal crime under DEA regulations covering Schedule II substances and puts both treatment and freedom at serious risk.

Split Dosing

When a prescriber determines that splitting a daily dose into two administrations is medically necessary, any portion the patient takes home counts as take-home medication and falls under the same supply limits. One split dose counts as a one-day supply for purposes of calculating the total.⁴

Random Callbacks

Many clinics use random callback procedures to control diversion. The patient is contacted without warning and given a short window, commonly 24 hours, to return to the clinic with their remaining take-home medication for a bottle count. Standard practice at most programs is about once per quarter. Failing a callback or declining without a valid reason raises immediate concerns about diversion and can result in reduced take-home privileges.

When Take-Home Privileges Can Be Revoked

The prescriber can deny, limit, or revoke take-home privileges at any time, even if a patient technically meets the regulatory minimums. This isn’t tied only to failed drug tests. A change in mental health status, an unstable housing situation, credible reports of medication sharing, or missed counseling sessions can all prompt a reassessment.¹

California’s regulations identify specific triggers that weigh against take-home eligibility:²

A positive drug screen for any unauthorized substance.
Evidence of criminal activity, including drug sales.
Irregular clinic attendance for dosing or counseling.
Behavioral problems at the program.
A destabilized home environment, such as a new household member with active substance use.

Revocation typically means returning to daily observed dosing and re-establishing eligibility through the same criteria used for initial approval. Some prescribers step a patient down one supply level as a warning; others pull all take-home privileges at once depending on the severity of the concern. The regulation doesn’t prescribe a single response, so experiences vary between programs.

The Old Step System You May Still Hear About

Before October 1, 2025, California used a six-step progression codified in Title 9, Section 10375. Patients who established their take-home schedules under that framework may still hear step-level terminology from their treatment team during the transition. The former schedule ran as follows:⁵

Step I (Days 1–90): up to one take-home dose per week, with at least six clinic visits.
Step II (Days 91–180): up to a two-day supply per week, with at least five clinic visits.
Step III (Days 181–270): up to a three-day supply per week, with at least four clinic visits.
Step IV (Days 271 to 1 year): up to a six-day supply per week, with clinic attendance reduced to once weekly.
Step V (after 1 year): up to a two-week supply, with at least two clinic visits per month.
Step VI (after 2 years): up to a one-month supply, with at least one clinic visit per month.

The shift is substantial. A patient who once needed nine months of flawless compliance just to earn a six-day supply can now receive a two-week supply within the first month, provided the clinical criteria are met.

Guest Dosing When You Travel

Patients who need to travel can receive doses at a different Opioid Treatment Program through guest dosing rather than relying on take-homes alone. The medical director or prescriber at your home clinic must determine that you’re unable to access your regular program, and the reason must be documented at both clinics.¹ Contact your program early. Not every OTP accepts guest patients, some charge a daily fee, and the paperwork transfer takes time.

Patient Rights and Grievance Procedures

If your take-home privileges are denied or revoked and you believe the decision was wrong, federal regulations require every OTP to maintain a formal complaint and grievance process. Patients disagreeing with take-home decisions must have access to recourse, and the program cannot retaliate for a complaint.³

Accrediting bodies must respond to patient complaints within five business days of receipt. Beyond the clinic level, each state has a State Opioid Treatment Authority that reviews exception requests and consults with SAMHSA on complaints. In California, DHCS holds that role. Start by filing a written complaint with your clinic’s patient advocate or director. If the internal process feels inadequate, escalate to DHCS.

1
eCFR. 42 CFR Part 8 – Medications for the Treatment of Opioid Use Disorder – Section 8.12
2
Cornell Law School. California Code of Regulations Title 9, 10370 – Criteria for Take-Home Medication Privileges
3
Federal Register. Medications for the Treatment of Opioid Use Disorder
4
Cornell Law School. California Code of Regulations Title 9, 10386 – Split Doses
5
Cornell Law School. California Code of Regulations Title 9, 10375 – Step Level Schedules for Methadone Take-Home Medication Privileges